Cargando…
Integrating scRNA and bulk-RNA sequencing develops a cell senescence signature for analyzing tumor heterogeneity in clear cell renal cell carcinoma
INTRODUCTION: Cellular senescence (CS) plays a critical role in cancer development, including clear cell renal cell carcinoma (ccRCC). Traditional RNA sequencing cannot detect precise molecular composition changes within tumors. This study aimed to analyze cellular senescence’s biochemical character...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10370498/ https://www.ncbi.nlm.nih.gov/pubmed/37503331 http://dx.doi.org/10.3389/fimmu.2023.1199002 |
_version_ | 1785077946026819584 |
---|---|
author | Gong, Qiming Jiang, Yan Xiong, Junfeng Liu, Fahui Guan, Jikui |
author_facet | Gong, Qiming Jiang, Yan Xiong, Junfeng Liu, Fahui Guan, Jikui |
author_sort | Gong, Qiming |
collection | PubMed |
description | INTRODUCTION: Cellular senescence (CS) plays a critical role in cancer development, including clear cell renal cell carcinoma (ccRCC). Traditional RNA sequencing cannot detect precise molecular composition changes within tumors. This study aimed to analyze cellular senescence’s biochemical characteristics in ccRCC using single RNA sequencing (ScRNA-seq) and traditional RNA sequencing (Bulk RNA-seq). METHODS: Researchers analyzed the biochemical characteristics of cellular senescence in ccRCC using ScRNA-seq and Bulk RNA-seq. They combined these approaches to identify differences between malignant and non-malignant phenotypes in ccRCC across three senescence-related pathways. Genes from these pathways were used to identify molecular subtypes associated with senescence, and a new risk model was constructed. The function of the gene DUSP1 in ccRCC was validated through biological experiments. RESULTS: The combined analysis of ScRNA-seq and Bulk RNA-seq revealed significant differences between malignant and non-malignant phenotypes in ccRCC across three senescence-related pathways. Researchers identified genes from these pathways to identify molecular subtypes associated with senescence, constructing a new risk model. Different subgroups showed significant differences in prognosis level, clinical stage and grade, immune infiltration, immunotherapy, and drug sensitivity. DISCUSSION: Senescence signature markers are practical biomarkers and predictors of molecular typing in ccRCC. Differences in prognosis level, clinical stage and grade, immune infiltration, immunotherapy, and drug sensitivity between different subgroups indicate that this approach could provide valuable insights into senescence-related treatment options and prognostic assessment for patients with ccRCC. The function of the gene DUSP1 in ccRCC was validated through biological experiments, confirming its feasibility as a novel biomarker for ccRCC. These findings suggest that targeted therapies based on senescence-related mechanisms could be an effective treatment option for ccRCC. |
format | Online Article Text |
id | pubmed-10370498 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103704982023-07-27 Integrating scRNA and bulk-RNA sequencing develops a cell senescence signature for analyzing tumor heterogeneity in clear cell renal cell carcinoma Gong, Qiming Jiang, Yan Xiong, Junfeng Liu, Fahui Guan, Jikui Front Immunol Immunology INTRODUCTION: Cellular senescence (CS) plays a critical role in cancer development, including clear cell renal cell carcinoma (ccRCC). Traditional RNA sequencing cannot detect precise molecular composition changes within tumors. This study aimed to analyze cellular senescence’s biochemical characteristics in ccRCC using single RNA sequencing (ScRNA-seq) and traditional RNA sequencing (Bulk RNA-seq). METHODS: Researchers analyzed the biochemical characteristics of cellular senescence in ccRCC using ScRNA-seq and Bulk RNA-seq. They combined these approaches to identify differences between malignant and non-malignant phenotypes in ccRCC across three senescence-related pathways. Genes from these pathways were used to identify molecular subtypes associated with senescence, and a new risk model was constructed. The function of the gene DUSP1 in ccRCC was validated through biological experiments. RESULTS: The combined analysis of ScRNA-seq and Bulk RNA-seq revealed significant differences between malignant and non-malignant phenotypes in ccRCC across three senescence-related pathways. Researchers identified genes from these pathways to identify molecular subtypes associated with senescence, constructing a new risk model. Different subgroups showed significant differences in prognosis level, clinical stage and grade, immune infiltration, immunotherapy, and drug sensitivity. DISCUSSION: Senescence signature markers are practical biomarkers and predictors of molecular typing in ccRCC. Differences in prognosis level, clinical stage and grade, immune infiltration, immunotherapy, and drug sensitivity between different subgroups indicate that this approach could provide valuable insights into senescence-related treatment options and prognostic assessment for patients with ccRCC. The function of the gene DUSP1 in ccRCC was validated through biological experiments, confirming its feasibility as a novel biomarker for ccRCC. These findings suggest that targeted therapies based on senescence-related mechanisms could be an effective treatment option for ccRCC. Frontiers Media S.A. 2023-07-12 /pmc/articles/PMC10370498/ /pubmed/37503331 http://dx.doi.org/10.3389/fimmu.2023.1199002 Text en Copyright © 2023 Gong, Jiang, Xiong, Liu and Guan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Gong, Qiming Jiang, Yan Xiong, Junfeng Liu, Fahui Guan, Jikui Integrating scRNA and bulk-RNA sequencing develops a cell senescence signature for analyzing tumor heterogeneity in clear cell renal cell carcinoma |
title | Integrating scRNA and bulk-RNA sequencing develops a cell senescence signature for analyzing tumor heterogeneity in clear cell renal cell carcinoma |
title_full | Integrating scRNA and bulk-RNA sequencing develops a cell senescence signature for analyzing tumor heterogeneity in clear cell renal cell carcinoma |
title_fullStr | Integrating scRNA and bulk-RNA sequencing develops a cell senescence signature for analyzing tumor heterogeneity in clear cell renal cell carcinoma |
title_full_unstemmed | Integrating scRNA and bulk-RNA sequencing develops a cell senescence signature for analyzing tumor heterogeneity in clear cell renal cell carcinoma |
title_short | Integrating scRNA and bulk-RNA sequencing develops a cell senescence signature for analyzing tumor heterogeneity in clear cell renal cell carcinoma |
title_sort | integrating scrna and bulk-rna sequencing develops a cell senescence signature for analyzing tumor heterogeneity in clear cell renal cell carcinoma |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10370498/ https://www.ncbi.nlm.nih.gov/pubmed/37503331 http://dx.doi.org/10.3389/fimmu.2023.1199002 |
work_keys_str_mv | AT gongqiming integratingscrnaandbulkrnasequencingdevelopsacellsenescencesignatureforanalyzingtumorheterogeneityinclearcellrenalcellcarcinoma AT jiangyan integratingscrnaandbulkrnasequencingdevelopsacellsenescencesignatureforanalyzingtumorheterogeneityinclearcellrenalcellcarcinoma AT xiongjunfeng integratingscrnaandbulkrnasequencingdevelopsacellsenescencesignatureforanalyzingtumorheterogeneityinclearcellrenalcellcarcinoma AT liufahui integratingscrnaandbulkrnasequencingdevelopsacellsenescencesignatureforanalyzingtumorheterogeneityinclearcellrenalcellcarcinoma AT guanjikui integratingscrnaandbulkrnasequencingdevelopsacellsenescencesignatureforanalyzingtumorheterogeneityinclearcellrenalcellcarcinoma |